Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment.

被引：0
|
作者：
Cheon, Jaekyung
Kang, Beodeul
Jung, Sang-Hoon
Kim, Chan
Chon, Hongjae
机构：
[1] CHA Univ, Sch Med, CHA Bundang Med Ctr, Med Oncol,Dept Internal Med, Seongnam, South Korea
[2] CHA Univ, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea
[3] CHA Bundang Med Ctr, Seongnam Si, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
554
引用
下载
收藏
页码：554 / 554
页数：1
相关论文
共 50 条
  • [41] Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
    Chan, Stephen L.
    Ryoo, Baek-Yeol
    Mo, Frankie
    Chan, Landon L.
    Cheon, Jaekyung
    Li, Leung
    Wong, Kwan H.
    Yim, Nicole
    Kim, Hyeyeong
    Yoo, Changhoon
    JOURNAL OF HEPATOLOGY, 2024, 81 (02) : 258 - 264
  • [42] Nivolumab plus Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
    Tsang, Josephine
    Wong, Jeffrey Sum Lung
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Leung, Roland
    Chiu, Joanne
    Cheung, Tan to
    Yau, Thomas
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (06) : 589 - 598
  • [43] Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Akbulut, Zeynep
    Aru, Basak
    Aydin, Furkan
    Demirel, Gulderen Yanikkaya
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [44] Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients Efficacy and Safety of Combination
    Fiorica, Francesco
    Belluomini, Lorenzo
    Stefanelli, Antonio
    Santini, Alessandra
    Urbini, Benedetta
    Giorgi, Carlotta
    Frassoldati, Antonio
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (11): : 1101 - 1105
  • [45] Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Morales-Barrera, Rafael
    Villacampa, Guillermo
    Vidal, Natalia
    Figols, Mariona
    Giner, Julia
    Bonfill, Teresa
    Suarez, Cristina
    Diaz, Nely
    Mateo, Joaquin
    Gonzalez, Macarena
    Domenech, Montserrat
    Puente, Javier
    Carles, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (12): : 3556 - 3564
  • [46] Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
    Hung, Yi-Ping
    Shao, Yu-Yun
    Lee, Jan-Mou
    Hsu, Chiun
    Hsu, Chih-Hung
    Yang, Muh-Hwa
    Chao, Yee
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (02) : 144 - 150
  • [47] Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Rafael Morales-Barrera
    Guillermo Villacampa
    Natalia Vidal
    Mariona Figols
    Julia Giner
    Teresa Bonfill
    Cristina Suárez
    Nely Díaz
    Joaquín Mateo
    Macarena González
    Montserrat Domenech
    Javier Puente
    Joan Carles
    Clinical and Translational Oncology, 2023, 25 : 3556 - 3564
  • [48] UPPER GASTROINTESTINAL INFLAMMATION IN PATIENTS WITH IMMUNE-CHECKPOINT INHIBITOR INDUCED DIARRHOEA
    Fazal, Muhammad Waqas
    Spain, Lavinia
    Ibraheim, Hajir
    Yousaf, Nadia
    Gore, Martin
    Larkin, James
    Turajlic, Samra
    Powell, Nick
    Au, Lewis
    GUT, 2018, 67 : A66 - A67
  • [49] Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
    Yamazaki, N.
    Uhara, H.
    Fukushima, S.
    Uchi, H.
    Shibagaki, N.
    Kiyohara, Y.
    Tsutsumida, A.
    Namikawa, K.
    Okuyama, R.
    Otsuka, Y.
    Tokudome, T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 969 - 975
  • [50] Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
    Sho, Takuya
    Suda, Goki
    Ohara, Masatsugu
    Kohya, Risako
    Sasaki, Takashi
    Yoshida, Sonoe
    Hosoda, Shunichi
    Ogawa, Koji
    Kitagataya, Takashi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Baba, Masaru
    Yamamoto, Yoshiya
    Tsukuda, Yoko
    Meguro, Takashi
    Yamada, Ren
    Kobayashi, Tomoe
    Takagi, Tomofumi
    Sakamoto, Naoya
    TARGETED ONCOLOGY, 2024, 19 (05) : 769 - 778
12345